 Verve Therapeutics Inc. is set to go public Thursday, after the Massachusetts-based biotechnology companys upsized initial public offering priced overnight above the expected range to value the company at about 832.6 million. Verve, which focuses on genetic medicines for cardiovascular disease, said it sold 14.04 million shares in the IPO, which priced at 19 a share, to raise 266.7 million. 